SEARCH

SEARCH BY CITATION

References

  • Abassi ZA, Tate JE, Golomb E, Keiser HR (1992). Role of neutral endopeptidase in the metabolism of endothelin. Hypertension 20: 8995.
  • Ahmed SI, Thompson J, Coulson JM, Woll PJ (2000). Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium. Am J Respir Cell Mol Biol 22: 422431.
  • Alanen K, Deng DX, Chakrabarti S (2000). Augmented expression of endothelin-1, endothelin-3 and the endothelin-B receptor in breast carcinoma. Histopathology 36: 161167.
  • Anguelova E, Beuvon F, Leonard N, Chaverot N, Varlet P, Couraud PO et al. (2005). Functional endothelin ET B receptors are selectively expressed in human oligodendrogliomas. Brain Res Mol Brain Res 137: 7788.
  • Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S et al. (2008). A Phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 14: 62706276.
  • Asham E, Shankar A, Loizidou M, Fredericks S, Miller K, Boulos PB et al. (2001). Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ETA receptor antagonism. Br J Cancer 85: 17591763.
  • Bagnato A, Natali PG (2004). Endothelin receptors as novel targets in tumor therapy. J Transl Med 2: 16.
  • Bagnato A, Rosanò L (2008). The endothelin axis in cancer. Int J Biochem Cell Biol 40: 14431451.
  • Bagnato A, Tecce R, Moretti C, Di Castro V, Spergel D, Catt KJ (1995). Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res 1: 10591066.
  • Bagnato A, Salani D, Di Castro V, Wu-Wong JR, Tecce R, Nicotra R et al. (1999). Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 59: 720727.
  • Bagnato A, Cirilli A, Salani D, Simeone P, Muller A, Nicotra MR et al. (2002). Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res 62: 63816384.
  • Bagnato A, Rosanò L, Spinella F, Di Castro V, Tecce R, Natali PG (2004). Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res 64: 14361443.
  • Bagnato A, Spinella F, Rosanò L (2005). Emerging role of the endothelin axis in ovarian tumor progression. Endocr Relat Cancer 12: 761772.
  • Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D et al. (2007). In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 67: 38183826.
  • Battistini B, Berthiaume N, Kelland NF, Webb DJ, Kohan DE (2006). Profile of past and current clinical trials involving endothelin receptor antagonists: the novel ‘-sentan’ class of drug. Exp Biol Med (Maywood) 231: 653695.
  • Bell RF, Wisløff T, Eccleston C, Kalso E (2006). Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review. Br J Cancer 94: 15591567.
  • Berger Y, Bernasconi CC, Juillerat-Jeanneret L (2006). Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents. Exp Biol Med (Maywood) 231: 11111119.
  • Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M et al. (2000). Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406: 536540.
  • Bradbury RH, Bath C, Butlin RJ, Dennis M, Heys C, Hunt SJ et al. (1997). New non-peptide endothelin-A receptor antagonists: synthesis, biological properties, and structure-activity relationships of 5-(dimethylamino)-N-pyridyl-,-N-pyrimidinyl-,-N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides. J Med Chem 40: 9961004.
  • Bremnes T, Paasche JD, Mehlum A, Sandberg C, Bremnes B, Attramadal H (2000). Regulation and intracellular trafficking pathways of the endothelin receptors. J Biol Chem 275: 1759617604.
  • Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K et al. (2008). Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 14: 2836.
  • Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD et al. (2003). Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21: 679689.
  • Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA et al. (2007). A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110: 19591966.
  • Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM et al. (2008). Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res 14: 14641469.
  • Chichorro JG, Fiuza CR, Bressan E, Claudino RF, Leite DF, Rae GA (2010). Endothelins as pronociceptive mediators of the rat trigeminal system: Role of ETA and ETB receptors. Brain Res 1345: 7383.
  • Clozel M, Breu V, Gray GA, Kalina B, Löffler B-M, Burri K et al. (1994). Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270: 228235.
  • Curwen J, Hughes G, Hickinson M, Curtis N, Growcott JW, Isherwood B et al. (2007). The impact of ZD4054, a specific endothelin A receptor antagonist, on tumor blood supply, invasion, and the bone microenvironment. Mol Cancer Ther 6: abst A272.
  • Davenport AP (2002). International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 54: 219226.
  • Dawson LA, Maitland NJ, Turner AJ, Usmani BA (2004). Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. Br J Cancer 90: 15771582.
  • Del Bufalo D, Di Castro V, Biroccio A, Salani D, Rosanò L, Spinella F et al. (2002). Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clin Sci (Lond) 103 (Suppl. 48): 302S305S.
  • Demunter A, De Wolf-Peeters C, Degreef H, Stas M, van den Oord JJ (2001). Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch 438: 485491.
  • Dupuis J, Jasmin JF, Prié S, Cernacek P (2000). Importance of local production of endothelin-1 and of the ETB receptor in the regulation of pulmonary vascular tone. Pulm Pharmacol Ther 13: 135140.
  • Egidy G, Juillerat-Jeanneret L, Jeannin JF, Korth P, Bosman FT, Pinet F (2000). Modulation of human colon tumor-stromal interactions by the endothelin system. Am J Pathol 157: 18631874.
  • Ferrero E, Labalde M, Fernández N, Monge L, Salcedo A, Narvaez-Sanchez R et al. (2008). Response to endothelin-1 in arteries from human colorectal tumours: role of endothelin receptors. Exp Biol Med 233: 16021607.
  • Firth JD, Ratcliffe PJ (1992). Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression. J Clin Invest 90: 10231031.
  • Fukami T, Nagase T, Fujita K, Hayama T, Niiyama K, Mase T et al. (1995). Structure-activity relationships of cyclic pentapeptide endothelin A receptor antagonists. J Med Chem 38: 43094324.
  • Fukui R, Nishimori H, Hata F, Yasoshima T, Ohno K, Yanai Y et al. (2007). Inhibitory effect of endothelin A receptor blockade on tumor growth and liver metastasis of a human gastric cancer cell line. Gastric Cancer 10: 123128.
  • Godara G, Cannon GW, Cannon GM Jr, Bies RR, Nelson JB, Pflug BR (2005). Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma. Prostate 65: 2734.
  • Goldie RG (1999). Endothelins in health and disease: an overview. Clin Exp Pharmacol Physiol 26: 145148.
  • Grant K, Knowles J, Dawas K, Burnstock G, Taylor I, Loizidou M (2007). Mechanisms of endothelin 1-stimulated proliferation in colorectal cancer cell lines. Br J Surg 94: 106112.
  • Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR (2004). A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res 64: 24612468.
  • Growcott JW (2009). Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drugs 20: 8388.
  • Guise TA, Yin JJ, Mohammad KS (2003). Role of endothelin-1 in osteoblastic bone metastases. Cancer 97: 779784.
  • Gulati A, Rai A (2004). Endothelin-1-induced vasodilatation in rat breast tumor is mediated through endothelin-B receptors. J Cardiovasc Pharmacol 44 (Suppl. 1): S483S486.
  • Guruli G, Pflug BR, Pecher S, Makarenkova V, Shurin MR, Nelson JB (2004). Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops. Blood 104: 21072115.
  • Ishikawa K, Fukami T, Nagase T, Fujita K, Hayama T, Niiyama K et al. (1992). Cyclic pentapeptide endothelin antagonists with high ETA selectivity. Potency- and solubility-enhancing modifications. J Med Chem 35: 21392142.
  • Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T et al. (1994). Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A 91: 48924896.
  • James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T et al. (2009). Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomized, Phase II trial. Eur Urol 55: 11121123.
  • James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P et al. (2010). Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int 106: 966973.
  • Jerónimo C, Henrique R, Campos PF, Oliveira J, Caballero OL, Lopes C et al. (2003). Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J Clin Pathol 56: 5255.
  • Juergens UR, Racké K, Uen S, Haag S, Lamyel F, Stöber M et al. (2008). Inflammatory responses after endothelin B (ETB) receptor activation in human monocytes: new evidence for beneficial anti-inflammatory potency of ETB-receptor antagonism. Pulm Pharmacol Ther 21: 533539.
  • Kandalaft LE, Facciabene A, Buckanovich RJ, Coukos G (2009). Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res 15: 45214528.
  • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411422.
  • Karet FE, Davenport AP (1996). Localization of endothelin peptides in human kidney. Kidney Int 49: 382387.
  • Kefford R, Beith JM, Van Hazel GA, Millward M, Trotter JM, Wyld DK et al. (2007). A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs 25: 247252.
  • Kefford RF, Clingan PR, Brady B, Ballmer A, Morganti A, Hersey P (2010). A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Mol Cancer 9: 69.
  • Kelland NF, Webb DJ (2006). Clinical trials of endothelin antagonists in heart failure: a question of dose? Exp Biol Med (Maywood) 231: 696699.
  • Khodorova A, Montmayeur J-P, Strichartz G (2009). Endothelin receptors and pain. J Pain 10: 428.
  • Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ (2008). The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 153: 11051119.
  • Knight LJ, Burrage J, Bujac SR, Haggerty C, Graham A, Gibson NJ et al. (2009). Epigenetic silencing of the endothelin-B receptor gene in non-small cell lung cancer. Int J Oncol 34: 465471.
  • Kohan DE (1997). Endothelins in the normal and diseased kidney. Am J Kidney Dis 29: 226.
  • Kuc RE, Davenport AP (2004). Comparison of endothelin-A and endothelin-B receptor distribution visualized by radioligand binding versus immunocytochemical localization using subtype selective antisera. J Cardiovasc Pharmacol 44 (Suppl. 1): S224S226.
  • Lahav R (2005). Endothelin receptor B is required for the expansion of melanocyte precursors and malignant melanoma. Int J Dev Biol 49: 173180.
  • Lahav R, Heffner G, Patterson PH (1999). An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci U S A 96: 1149611500.
  • Lambert LA, Whyteside AR, Turner AJ, Usmani BA (2008). Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion. Br J Cancer 99: 11141120.
  • Leung PS (2004). The peptide hormone angiotensin II: its new functions in tissues and organs. Curr Protein Pept Sci 5: 267273.
  • Levin ER (1995). Endothelins. N Engl J Med 333: 356363.
  • Manola J, Carducci M, Nair S, Liu G, Rousey S, Wilding G (2007). Phase II ECOG trial of atrasentan in advanced renal cell carcinoma. J Clin Oncol 25: abst 5102.
  • Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR (2006). Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 107: 530535.
  • Molenaar P, O'Reilly G, Sharkey A, Kuc RE, Harding DP, Plumpton C et al. (1993). Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res 72: 526538.
  • Morris CD, Hughes A, Rose A, Melville V, Webb DJ (2005a). ZD4054 reduces endothelin-1-induced forearm vasoconstriction in healthy male volunteers. Proc Am Assoc Cancer Res 46: abst 4187.
  • Morris CD, Rose A, Curwen J, Hughes AM, Wilson DJ, Webb DJ (2005b). Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 92: 21482152.
  • Motte S, McEntee K, Naeije R (2006). Endothelin receptor antagonists. Pharmacol Ther 110: 386414.
  • Nelson JB (2003). Endothelin inhibition: novel therapy for prostate cancer. J Urol 170: S65S68.
  • Nelson JB (2009). Endothelin receptors as therapeutic targets in castration-resistant prostate cancer. Eur Urol Suppl 8: 2028.
  • Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA et al. (1995). Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1: 944949.
  • Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS et al. (1996). Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56: 663668.
  • Nelson JB, Lee W-H, Nguyen SH, Jarrard DF, Brooks JD, Magnuson SR et al. (1997). Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 57: 3537.
  • Nelson J, Bagnato A, Battistini B, Nisen P (2003). The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110116.
  • Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ et al. (2008). Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113: 24782487.
  • Nunez DJ, Brown MJ, Davenport AP, Neylon CB, Schofield JP, Wyse RK (1990). Endothelin-1 mRNA is widely expressed in porcine and human tissues. J Clin Invest 85: 15371541.
  • Nussdorfer GG, Rossi GP, Malendowicz LK, Mazzocchi G (1999). Autocrine-paracrine endothelin system in the physiology and pathology of steroid-secreting tissues. Pharmacol Rev 51: 403438.
  • Okada M, Nishikibe M (2002). BQ-788, a selective endothelin ETB receptor antagonist. Cardiovasc Drug Rev 20: 5366.
  • Okazawa M, Shiraki T, Ninomiya H, Kobayashi S, Masaki T (1998). Endothelin-induced apoptosis of A375 human melanoma cells. J Biol Chem 273: 1258412592.
  • Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB et al. (1996). Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 276: 473481.
  • Pao MM, Tsutsumi M, Liang G, Uzvolgyi E, Gonzales FA, Jones PA (2001). The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum Mol Genet 10: 903910.
  • Paolillo M, Russo MA, Curti D, Lanni C, Schinelli S (2010). Endothelin B receptor antagonists block proliferation and induce apoptosis in glioma cells. Pharmacol Res 61: 306315.
  • Phuphanich S, Carson KA, Grossman SA, Lesser G, Olson J, Mikkelsen T et al. (2008). Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro Oncol 10: 617623.
  • Rai A, Rajeshkumar NV, Gulati A (2006). Effect of the ETB receptor agonist, IRL-1620, on paclitaxel plasma pharmacokinetics of breast tumor rats. Exp Biol Med (Maywood) 231: 11201122.
  • Resink TJ, Hahn AW, Scott-Burden T, Powell J, Weber E, Buhler FR (1990). Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem Biophys Res Commun 168: 13031310.
  • Rosanò L, Varmi M, Salani D, Di Castro V, Spinella F, Natali PG et al. (2001). Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 61: 83408346.
  • Rosanò L, Spinella F, Salani D, Di Castro V, Venuti A, Nicotra MR et al. (2003). Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 63: 24472453.
  • Rosanò L, Di Castro V, Spinella F, Nicotra MR, Natali PG, Bagnato A (2007a). ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther 6: 20032011.
  • Rosanò L, Di Castro V, Spinella F, Tortora G, Nicotra MR, Natali PG et al. (2007b). Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res 67: 63516359.
  • Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A et al. (2009). Beta-arrestin links endothelin A receptor to betacatenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A 106: 28062811.
  • Rubanyi GM, Polokoff MA (1994). Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46: 325415.
  • Russell FD, Davenport AP (1999). Secretory pathways in endothelin synthesis. Br J Pharmacol 126: 391398.
  • Salani D, Di Castro V, Nicotra MR, Rosano L, Tecce R, Venuti A et al. (2000). Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 157: 15371547.
  • Schinelli S (2006). Pharmacology and physiopathology of the brain endothelin system: an overview. Curr Med Chem 13: 627638.
  • Schmidt BL, Pickering V, Liu S, Quang P, Dolan J, Connelly ST et al. (2007). Peripheral endothelin A receptor antagonism attenuates carcinoma-induced pain. Eur J Pain 11: 406414.
  • Sekulic A, Suresh P, Pittelkow MR, Markovic S (2002). Bosentan, a novel endothelin-A and -B receptor antagonist inhibits proliferation of malignant melanoma cells. (Abstract) Meeting of the American Association for Cancer Research. Mayo Clinic: Rochester, MN, USA.
  • Selting K, Kolli P, Henry C, Owen N, Wipke-Tevis D, Eisen M et al. (2008). Use of a novel endothelin-B agonist (SPI-1620) to alter blood flow to solid tumors for improved chemotherapy delivery in dogs with spontaneously-occurring tumors. Proc Am Assoc Cancer Res 49: abst 365.
  • Smollich M, Wülfing P (2007). The endothelin axis: a novel target for pharmacotherapy of female malignancies. Curr Vasc Pharmacol 5: 239248.
  • Smollich M, Wülfing P (2008). Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers. Expert Rev Anticancer Ther 8: 14811493.
  • Spinella F, Garrafa E, Di Castro V, Rosanò L, Nicotra MR, Caruso A et al. (2009). Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res 69: 26692676.
  • Spratt JC, Goddard J, Patel N, Strachan FE, Rankin AJ, Webb DJ (2001). Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol 134: 648654.
  • Takai M, Umemura I, Yamasaki K, Watakabe T, Fujitani Y, Oda K et al. (1992). A potent and specific agonist, Suc-[Glu9,Ala11,15]-endothelin-1(8-21), IRL 1620, for the ETB receptor. Biochem Biophys Res Commun 184: 953959.
  • Tanese K, Fukuma M, Ishiko A, Sakamoto M (2010). Endothelin-2 is upregulated in basal cell carcinoma under control of Hedgehog signaling pathway. Biochem Biophys Res Commun 391: 486491.
  • Trump DL, Payne H, Miller K, de Bono JS, Stephenson J, Burris HA et al. (2010). Safety and efficacy of the specific endothelin A receptor antagonist zibotentan (ZD4054) plus docetaxel in patients with metastatic hormone-resistant prostate cancer: results of a phase I study. ASCO-GU Symposium San Francisco, CA, USA, 5–7 March abst 193.
  • Verri WA Jr, Cunha TM, Magro DA, Guerrero AT, Vieira SM, Carregaro V et al. (2009). Targeting endothelin ETA and ETB receptors inhibits antigen-induced neutrophil migration and mechanical hypernociception in mice. Naunyn Schmiedebergs Arch Pharmacol 379: 271279.
  • Wang HH, Hsieh HL, Wu CY, Yang CM (2010). Endothelin-1 enhances cell migration via matrix metalloproteinase-9 up-regulation in brain astrocytes. J Neurochem 113: 11331149.
  • Wiesmann F, Veeck J, Galm O, Hartmann A, Esteller M, Knuchel R et al. (2009). Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer. Breast Cancer Res 11: R34.
  • Wu-Wong JR, Dixon DB, Chiou WJ, Sorensen BK, Liu G, Jae H-S et al. (2002). Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies. Clin Sci (Lond) 103 (Suppl. 48): 107S111S.
  • Yuyama H, Sanagi M, Koakutsu A, Mori M, Fujimori A, Harada H et al. (2003). Pharmacological characterization of YM598, an orally active and highly potent selective endothelin ETA receptor antagonist. Eur J Pharmacol 478: 6171.
  • Yuyama H, Koakutsu A, Fujiyasu N, Fujimori A, Sato S, Shibasaki K et al. (2004a). Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. J Cardiovasc Pharmacol 44 (Suppl. 1): S479S482.
  • Yuyama H, Koakutsu A, Fujiyasu N, Tanahashi M, Fujimori A, Sato S et al. (2004b). Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain. Eur J Pharmacol 492: 177182.
  • Zhang W-M, Zhou J, Ye Q-J (2008). Endothelin-1 enhances proliferation of lung cancer cells by increasing intracellular free Ca2+. Life Sci 82: 764771.